Physician profile
Andreas Syllaba
NPI 1063500932
$4,190.13
in general payments reported to CMS, 2019-2025
38 companies · $700 in 2025
The $700 reported for 2025 was more than what 82% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $173 · 2021: $536 · 2022: $1,164 · 2023: $729 · 2024: $616 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $787.08 | 2020-2025 | Xtampza, Belbuca |
| Abbvie INC. | $561.95 | 2022-2025 | Botox, Ubrelvy |
| Boston Scientific Corporation | $469.79 | 2020-2025 | General - Pain Management |
| Medtronic, INC. | $456.27 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Pfizer INC. | $196.88 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.03 | 2020-2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $124.19 | 2020-2023 | Austedo Xr, Austedo |
| Grt US Holding, INC. | $124.01 | 2022 | |
| Medtronic USA, INC. | $117.28 | 2019 | |
| Abbott Laboratories | $99.80 | 2022-2025 | Proclaim, Eterna |
| Biohaven Pharmaceutical Holding Company LTD. | $95.76 | 2022 | |
| Averitas Pharma INC. | $86.46 | 2023-2025 | Qutenza |
| Nevro Corp. | $86.02 | 2019 | |
| Jazz Pharmaceuticals INC. | $69.29 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $66.71 | 2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $64.49 | 2020-2021 | |
| Tersera Therapeutics LLC | $56.38 | 2022-2025 | Prialt |
| Ibsa Pharma INC. | $54.85 | 2022-2024 | Licart, Tirosint |
| Nalu Medical, INC. | $49.39 | 2021 | |
| Amgen INC. | $48.67 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $44.93 | 2022-2025 | Ztlido |
| Merz Pharmaceuticals, LLC | $42.70 | 2024-2025 | Xeomin |
| Stimwave Technologies Incorporated | $42.06 | 2021 | |
| Axsome Therapeutics, INC. | $28.32 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $27.53 | 2023 | Lyvispah |
| Mdd US Operations, LLC | $27.08 | 2022 | |
| Lundbeck LLC | $25.25 | 2024 | Vyepti |
| Globus Medical, INC. | $24.28 | 2025 | Senza |
| Biodelivery Sciences International, INC. | $23.94 | 2020-2021 | |
| Painteq LLC | $23.88 | 2023 | Painteq |
| Saluda Medical Americas, INC. | $16.31 | 2025 | Evoke |
| Tonix Medicines, INC. | $15.96 | 2025 | Tonmya |
| Lilly USA, LLC | $15.11 | 2023 | Emgality, Reyvow |
| Kowa Pharmaceuticals America, INC. | $14.14 | 2023 | Livalo, Seglentis |
| Biohaven Pharmaceuticals, INC. | $13.95 | 2021 | |
| Curonix LLC | $13.94 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Depuy Synthes Sales INC. | $13.46 | 2025 | Monovisc, Orthovisc |
| Bioventus LLC | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Syllaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.